Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria (All Subjects):~* Male or female (sterile or postmenopausal) subjects between 18-75 (both inclusive) years of age and healthy as determined by absence of clinically significant deviation from normal in medical history, physical examination, vital signs, electrocardiograms, and clinical laboratory determinations (except for renal impaired subjects).~* Subjects must have a BMI between 18 kg/m2 and 38 kg/m2 and weight at least 50 kg and no more than 120 kg.~* Additional inclusion criteria for subjects with normal renal function:~  * An absolute GFR as determined by MDRD equation and conversion within normal range as determined by GFR \> 90 mL/min~Inclusion Criteria (for subjects with impaired renal function):~- Subjects must have documented stable renal disease without evidence of renal progressive disease (stable renal disease is defined as no significant change, such as a stable absolute GFR, for 4 weeks prior to study entry.~Exclusion Criteria (All Subjects):~* Subject has received a renal transplant at any time in the past and is on immunosuppressant therapy~* History or presence of impaired cardiac function~* Any surgical or medical condition that may significantly alter the absorption, distribution, metabolism, or excretion of drugs~* Administration of CYP3A4/5 inhibitors or inducers or CYP3A4 substrates with narrow therapeutic windows~* Administration of medications that prolong the QT interval~* Subject has a history of immunodeficiency diseases, including HIV, as confirmed by (HIV-1, HIV-2) test~* Receipt of investigational product in another clinical trial within 4 weeks of dosing~Exclusion Criteria (for subjects with impaired renal function):~* Severe albuminuria \> 300 mg/day~* Subjects undergoing any method of dialysis~* Subjects with renal impairment due to hepatic disease (hepatorenal syndrome)~Other protocol-defined Inclusion/Exclusion may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Normal renal function (Type: EXPERIMENTAL): Normal renal function; matched demography to renal impariment cohorts
- Severe renal impairment (Type: EXPERIMENTAL): Severe decrease in GFR (15-29 ml/min)
- End Stage Renal Disease (Type: EXPERIMENTAL): End stage renal disease not on dialysis; GFR \<15 ml/min
- Mild renal impairment (Type: EXPERIMENTAL): Mild decrease in GFR (60-89 ml/min)
- Moderate renal impairment (Type: EXPERIMENTAL): Moderate decrease in GFR (30-59 ml/min)

Based on this trial design, predict the completion outcome and termination type (if applicable).